İbrahim ORMAN, HÜLYA TAŞKAPAN, MEHMET ÇAĞATAY TAŞKAPAN, Fatma ÖZYALIN, İrfan KUKU

Vitamin D and pro-inflammatory cytokine IFN-γ and the anti-inflammatory cytokines IL-4 and IL-10 in peritoneal dialysis patients

Several clinical trials in patients with chronic disease have found that active vitamin D usage lowers pro-inflammatory cytokines. The aim of this study was evaluate whether supplementation of cholecalciferol in peritoneal dialysis patients with vitamin D deficiency would lead any chance in the pro-inflammatory cytokine IFN-γ and the anti-inflammatory cytokines IL-4 and IL-10, and pentraxin 3 and peripheral blood mononuclear cell subpopulations (CD3, CD4, CD8, CD45)and CD4/CD8 ratio. We analyzed fasting blood samples from 31 continuous peritoneal dialysis patients (15 males, 16 females, mean age 48,6±14,8 yrs) for serum 25-hydroxyvitamin D [25(OH)D)] and specific plasma cytokine concentrations (interferon-gamma [IFN-γ], interleukin [IL]-4, and IL-10), pentraxine 3, CD3, CD4, CD8 and CD45 before and after cholecalciferol replacement. Before and after cholecalciferol replacement mean 25 (OH) level was 6,1±2,1 ng/dL and 39,7±10,9 ng/dL respectively (p

PDF

___

1. Adams JS, Hewison M. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab. 2008;4(2):80-90.

2. Khoo AL, Koenen HJ, Chai LY, Sweep FC, Netea MG, van der Ven AJ, Joosten I. Seasonal variation in vitamin D₃ levels is paralleled by changes in the peripheral blood human T cell compartment. PLoS One. 2012;7(1):e29250.

3. Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25- dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys. 2000;374(2):334-8.

4. Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol. 2008;8(9):685-98.

5. Hewison M, Freeman L, Hughes SV, Evans KN, Bland R, Eliopoulos AG, Kilby MD, Moss PA, Chakraverty R. Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J. Immunol. 2003;170(11):5382-90.

6. Fritsche J, Mondal K, Ehrnsperger A, Andreesen R, Kreutz M. Regulation of 25-hydroxyvitaminD3–1 alpha-hydroxylase and production of 1 alpha,25-dihydroxyvitamin D3 by human dendritic cells. Blood. 2003;102(9):3314-16.

7. Inanir A, Ozoran K, Tutkak H, Mermerci B. The effects of calcitriol therapy on serum interleukin-1, interleukin-6 and tumour necrosis factor-alpha concentrations in post-menopausal patients with osteoporosis. J Int Med Res. 2004;32(6):570-82.

8. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supple-mentation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006;83(4):754-9.

9. Stenvinkel P. Inflammation in end- stage renal failure: could it be treated? Nephrol Dial Transplant. 2002;17(Supp 8): 33- 8.

10. Pecotis-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome – the heart of the matter. Nephrol Dial Transplant. 2002;17(Supp 11):28-31.

11. Taskapan H, Ersoy FF, Passadakis P, Tam P, Memmos D, Katopodis K, Ozener C, Akcicek F, Camsarı T, Ates K, Ataman R, Vlachojannis JG, Dombros N, Utas C, Akpolat T, Bozfakioglu S, Wu GG, Karayaylali I, Arınsoy T, Stathakis Ch, Yavuz M, Tsakiris D, Dimitriades A, Yılmaz ME, Gultekin M, Karayalcin B, Polat N, Oreopoulos DG. Severe vitamin D deficiency in chronic renal failure patients on peritoneal dialysis. Clin Nephrol. 2006;66(4):247-55.

12. Taskapan H, Wei M, Oreopoulos DG. 25(OH) Vitamin D(3) in patients with chronic kidney disease and those on dialysis: rediscovering its importance. Int Urol Nephrol. 2006;38(2):323-9.

13. Borazan A, Ustün H, Cefle A, Sekitmez N, Yilmaz A. Comparative efficacy of oral and intravenous calcitriol treatment in haemodialysis patients: effects on serum biochemistry and cytokine levels. J Int Med Res. 2003;31(6):489-96.

14. Haran N, Gurwicz S, Gallati H, Shalita B, Bar-Khayim Y. Effect of 1 alpha-hydroxyvitamin D3 treatment on production of tumor necrosis factor-alpha by peripheral blood mononuclear cells and on serum concentrations of soluble tumor necrosis factor receptors in hemodialysis patients. Nephron. 1994;66(3):262-6.

15. Tabata T, Shoji T, Kikunami K, Matsushita Y, Inoue T, Tanaka S, Hino M, Miki T, Nishizawa Y, Morii H. In vivo effect of 1 alphahydroxyvitamin D3 on interleukin-2 production in hemodialysis patients. Nephron. 1988;50(4):295-8.

16. Turk S, Akbulut M, Yildiz A, Gürbilek M, Gönen S, Tombul Z, Yeksan M. Comparative effect of oral pulse and intravenous calcitriol treatment in hemodialysis patients: the effect on serum IL-1 and IL-6 levels and bone mineral density. Nephron. 2002;90(2):188-94.

17. Wu CC, Chang JH, Chen CC, Su SB, Yang LK, Ma WY, Zheng CM, Diang LK, Lu KC.Calcitriol treatment attenuates inflammation and oxidative stress in hemodialysis patients with secondary hyperparathyroidism. Tohoku J Exp Med. 2011;223(3):153-9.

18. Dusso A, Lopez-Hilker S, Rapp N, Slatopolsky E. Extra-renal production of calcitriol in chronic renal failure. Kidney Int. 1988;34(3): 368-75.

19. Lambert PW, Stern PH, Avioli RC, Brackett NC, Turner RT, Greene A, Fu IY, Bell NH. Evidence for extrarenal production of 1 alpha,25-dihydroxyvitamin D in man. J Clin Invest. 1982;69(3): 722– 5.

20. Heine G, Niesner U, Chang HD, Steinmeyer A, Zügel U, Zuberbier T, Radbruch A, Worm M. 1,25-dihydroxyvitamin D (3) promotes IL10 production in human B cells. Eur J Immunol. 2008;38(8):2210-18.

21. ZittermannA, Dembinski J, Stehle P. Low vitamin D status is associated with low cord blood levels of the immunosuppressive cytokine interleukin-10. Pediatr Allergy Immunol. 2004;15(3):242-6.

22. Hewison M, Zehnder D, Chakraverty R, Adams JS. Vitamin D and barrier function: a novel role for extra-renal 1 alpha-hydroxylase. Mol Cell Endocrinol. 2004;215(1-2):31-8.

23. Holick MF.VitaminD. The underappreciated D-lightful hormone that is important for skeletal and cellular health.Curr Opin Endocrinol Diabetes. 2002;9(1):87-98.

24. Stubbs JR, Idiculla A, Slusser J, Menard R, Quarles LD. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol. 2010;21(2):353-61.

25. Bucharles S, Barberato SH, Stinghen AE, Gruber B, Piekala L, Dambiski AC, Custodio MR, Pecoits-Filho R. Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism. J Ren Nutr. 2012;22(2):284-91.

26. Assimon MM, Salenger PV, El-Fawal HA, Mason DL. Nutritional vitamin D supplementation in haemodialysis: A potential vascular benefit? Nephrology (Carlton). 2012;17(3):237-42.

27. Casciato DA, McAdam LP, Kopple JD, Bluestone R, Goldberg LS, Clements PJ, Knutson DW. Immunologic abnormalities in hemodialysis patients: improvement after pyridoxine therapy. Nephron. 1984;38(1):9-16.

28. Golden MHN, Golden BE, Harland PSEG, Jackson AA. Zinc and immunocompetence in protein anergy malnutrition. Lancet. 1978;1(1):1226-6.

29. Bender BS, Curtis JL, Nagel JA, Chrest FJ, Kraus ES, Briefel GR, Adler WH. Analysis of immune status of hemodialyzed adults: association with prior transfusions. Kidney Int. 1984;26(4): 436-43.